用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网科技动向生物医学
关键字  范围   
 
Unexpected Activity of 2 Enzymes Helps Explain Why Liver Cancer Drugs Fail
Unexpected Activity of 2 Enzymes Helps Explain Why Liver Cancer Drugs Fail
1/2/2017 5:33:06 AM | 浏览:508 | 评论:0

Overturning previous assumptions, study also provides new, more realistic model for liver cancer research and drug development

 
Some cancers are caused by loss of enzymes that should keep cell growth in check. On the flip side, some are caused by over-activation of enzymes that enhance cell growth. Yet drugs that inhibit the overactive enzymes have failed to work against liver cancer. In mouse models, researchers at University of California San Diego School of Medicine have discovered a potential reason — counterintuitively, lack of both types of these enzymes can lead to liver disease and cancer. In human liver tumor samples, they also found that deficiencies in these two enzymes, called Shp2 and Pten, are associated with poor prognosis.
 

Unexpected Activity of 2 Enzymes Helps Explain Why Liver Cancer Drugs Fail

Left to right:1)healthy mouse liver, 2)liver deficient for Shp2, 3)liver deficient for Pten, 4)liver deficient for both Shp2 and Pten. Tumors are visible in 3)and are even more prominent in 4), where both enzymes are lacking.

The study, published December 13 by Cell Reports, provides a new understanding of how liver cancer develops, a new therapeutic approach and new mouse model for studying the disease.

“When it comes to liver cancer, I think we’ve been making strategic mistakes,” said senior author Gen-Sheng Feng, PhD, professor of pathology and biological sciences at UC San Diego. “In cancer development, we always thought about two distinct families of enzymes — one promotes cancer, one inhibits it. Many drugs have been developed to block the cancer-promoting pathways, but we and others are now finding that many classical pro-cancer proteins are actually inhibitors.”

Based on Shp2’s well-known role in promoting tumor formation, researchers have long assumed that drugs that block the enzyme would inhibit tumor formation. But Feng’s team previously found the opposite to be true — loss of the Shp2 enzyme can promote liver cancer. In contrast, in a study published last year, Feng and team discovered that removing both Shp2 and Pten, a tumor-suppressing enzyme, neutralized leukemia development.

“So the roles of tumor-promoting and tumor-suppressing enzymes are not as simple

as we thought,” Feng said. “This also explains many unwanted side effects with drugs that target these enzymes. Their consequences can differ depending on cell type.”

In this latest study, Feng and team found that Shp2 and Pten cooperate to suppress liver tumor formation in experimental mice. When the researchers deleted both the Shp2 and Pten genes specifically in the mice’s liver cells, early-onset liver disease(non-alcoholic steatohepatitis, or NASH)was more severe and liver tumors occurred earlier and more frequently than in control mice with one or both enzymes functioning.

Normal mice did not experience any tumors. In mice lacking either Pten or Shp2, liver tumors began to appear after approximately seven or 12 months. But for mice lacking both enzymes, 80 percent spontaneously developed liver tumors in five months; 100 percent had tumors at seven months.

The increased severity of liver disease and frequency of liver cancer in these models is likely because lack of Shp2 and Pten enzymes activates molecules involved in lipid metabolism, inflammation and fibrosis, the researchers said.

After their surprising results in mice, the researchers wondered if the same phenomenon occurs in human liver cancers. They analyzed 335 human liver tumor samples and found that approximately 52 percent of the tumors were low in both Shp2 and Pten enzyme levels. Those patients with low Shp2 and Pten enzyme levels in the tumors had a poorer prognosis than those with higher levels of one or both enzymes — at 50 months after surgery, approximately 60 percent of patients with low Shp2 and Pten were alive, compared to approximately 90 percent of patients with high Shp2 and Pten levels.

These results provide new information about how liver cancer arises and a new target for drug development. But the findings also offer a new laboratory model for studying the disease. Previously, Feng’s team and others would use chemical carcinogens to induce liver cancer in mouse models. Instead of taking this artificial approach, Feng said researchers can now generate more realistic mouse models of non-alcoholic fatty liver disease and liver cancer simply by removing the Pten and Shp2 enzymes.

“Liver cancer is more complicated than we thought. These pathways, when over-activated, stimulate tumor development, but so does inhibiting them,” Feng said. “That’s why we can’t rush to conclusions like we have in the past. But now that we have a good model that mimics the human pathogenic process and we can use that to work out the mechanisms that lead to liver disease and cancer, and search for novel drug targets.”

Co-authors of this study include:Xiaolin Luo, Kaisa L. Hanley, Helen He Zhu, Kirsten N. Malo, Carolyn Hernandez, Nissi M. Varki, Nazilla Alderson, Catherine Chu, Shuangwei Li, Rohit Loomba, UC San Diego; Rui Liao, UC San Diego, Fudan University, and Chongqing Medical Unversity; Xufu Wei, UC San Diego, and Chongqing Medical University; Jia Fan, Shuang-Jian Qiu, Fudan University.

This research was funded, in part, by the National Institutes of Health(R01CA176012, R01CA188506)and UC San Diego-Roche Extending Innovation Network.

相关栏目:『生物医学
CAR-T细胞:“免疫系统的守卫者” 2017-07-19 [11]
手机点一点就能轻松避孕 — 来自瑞典的避孕APP 2017-07-19 [25]
近期癌症免疫疗法研究领域的突破性进展 2017-07-18 [50]
国际空间站测试癌症新疗法 2017-07-17 [40]
《Cell》:宾夕法尼亚大学科学家破解癌细胞新阴谋 2017-07-16 [53]
西班牙的研究人員發現:慢性病與出生月份存在關聯 2017-07-16 [54]
CAR-T技术开发的历史和现状 2017-07-11 [152]
DNA技术新突破: 从一滴血或一缕头发中预测恐怖分子的长相 2017-07-09 [121]
卡内基梅隆大学:人工智能新突破 可理解人类思想 2017-07-09 [143]
《自然》:美德两国团队同时宣布,抗癌个性化疫苗首次大获成功 2017-07-07 [262]
相关栏目更多文章
最新图文:
:中国未来的生存法则 :CAR-T细胞:“免疫系统的守卫者” :袁劲梅教授写给自己被开除的中国留学生的信 :妙语悬鉴30联 :《全球软实力排名》:法国第一,中美法各有滋味 :手机点一点就能轻松避孕 — 来自瑞典的避孕APP :2017 QS全球大学排名 美国大学在前十名中占5位 :鲍捷:知识图谱在金融领域的发展与应用
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2017 ScholarsUpdate.com. All Rights Reserved.